You are viewing the site in preview mode
Skip to main content
| |
Healthy Controls (n = 8)
|
Fabry Disease Patients (n = 38)
|
p-value
|
|---|
|
LVEDV (mL)
|
178.5 ± 46.4
|
154.6 ± 34.9
|
0.16
|
|
LVEDVi (mL/m2)
|
96.3 ± 13.9
|
84.2 ± 20.2
|
0.043
|
|
LVESV (mL)
|
73.1 ± 23.8
|
63.2 ± 18.1
|
0.23
|
|
LVESVi (mL/m2)
|
39.3 ± 8.7
|
34.4 ± 10.3
|
0.10
|
|
LVSV (mL)
|
105.4 ± 23.3
|
91.4 ± 20.0
|
0.09
|
|
LVEF (%)
|
59.6 ± 3.6
|
59.31 ± 4.6
|
0.86
|
|
Cardiac output (L/min)
|
6.3 ± 1.5
|
6.2 ± 1.2
|
0.86
|
|
LV mass (g)
|
99.9 ± 37.1
|
131.2 ± 57.8
|
0.22
|
|
LVMi (g/m2)
|
53.4 ± 15.7
|
71.0 ± 31.5
|
0.21
|
|
LGE (presence)
|
0.0 (0%)
|
17 (45%)
|
0.019
|
|
LGE (%)
|
0.0 ± 0.0
|
2.0 ± 3.5
|
< 0.001
|
|
Native T1 (ms)
|
1239.0 ± 18.0
|
1170.2 ± 37.5
|
< 0.001
|
|
ECV (%)
|
25.9 ± 3.2
|
25.6 ± 2.9
|
0.48
|
|
GLS (%)
|
-16.3 ± 1.5
|
−15.3 ± 3.5
|
0.45
|
|
GCS (%)
|
−19.5 ± 2.9
|
−19.4 ± 3.0
|
0.84
|
|
Base-to-apex LS gradient (%)
|
9.3 ± 3.5
|
7.5 ± 3.8
|
0.24
|
|
Base-to-apex CS gradient (%)
|
6.5 ± 2.2
|
2.1 ± 3.7
|
0.002
|
- Comparisons between groups were made by independent samples t-test, Wilcoxon rank sum test or Fisher’s exact test. Continuous variables are presented as mean ± SD. Categorical variables are presented as number of subjects with percentage in parentheses. CS circumferential strain, ECV extracellular volume, FD Fabry disease, GCS global circumferential strain, GLS global longitudinal strain, LGE late gadolinium enhancement, LS longitudinal strain, LV Left ventricle, LVMi left ventricular mass indexed to body surface area (BSA), LVEF left ventricular ejection fraction, LVEDV left ventricular end diastolic volume, LVEDVi LVEDV indexed to BSA, LVESV left ventricular end systolic volume, LVESVi LVESV indexed to BSA, LVSV left ventricular stroke volume
